JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 106 filers reported holding JOUNCE THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 1.23 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $40,000 | -54.0% | 13,099 | 0.0% | 0.00% | +200.0% |
| Q1 2022 | $87,000 | -20.2% | 13,099 | 0.0% | 0.00% | -85.7% |
| Q4 2021 | $109,000 | +12.4% | 13,099 | 0.0% | 0.01% | 0.0% |
| Q3 2021 | $97,000 | +9.0% | 13,099 | 0.0% | 0.01% | +16.7% |
| Q2 2021 | $89,000 | -34.1% | 13,099 | 0.0% | 0.01% | -40.0% |
| Q1 2021 | $135,000 | -28.9% | 13,099 | -51.7% | 0.01% | -37.5% |
| Q4 2020 | $190,000 | -14.0% | 27,099 | 0.0% | 0.02% | -20.0% |
| Q3 2020 | $221,000 | +18.2% | 27,099 | 0.0% | 0.02% | +17.6% |
| Q2 2020 | $187,000 | +45.0% | 27,099 | 0.0% | 0.02% | -19.0% |
| Q1 2020 | $129,000 | -45.6% | 27,099 | 0.0% | 0.02% | -44.7% |
| Q4 2019 | $237,000 | +163.3% | 27,099 | 0.0% | 0.04% | +192.3% |
| Q3 2019 | $90,000 | -32.8% | 27,099 | 0.0% | 0.01% | -35.0% |
| Q2 2019 | $134,000 | -20.2% | 27,099 | 0.0% | 0.02% | -13.0% |
| Q1 2019 | $168,000 | +84.6% | 27,099 | 0.0% | 0.02% | +64.3% |
| Q4 2018 | $91,000 | -48.3% | 27,099 | 0.0% | 0.01% | -17.6% |
| Q3 2018 | $176,000 | -15.4% | 27,099 | 0.0% | 0.02% | -43.3% |
| Q2 2018 | $208,000 | -65.7% | 27,099 | 0.0% | 0.03% | -64.7% |
| Q1 2018 | $606,000 | – | 27,099 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TRV GP II, LLC | 572,829 | $1,340,000 | 100.00% |
| TRV GP III, LLC | 1,148,780 | $2,688,000 | 1.17% |
| COWEN AND COMPANY, LLC | 3,647,430 | $8,535,000 | 0.82% |
| Octagon Capital Advisors LP | 1,400,000 | $3,276,000 | 0.56% |
| Deep Track Capital, LP | 4,259,653 | $9,968,000 | 0.46% |
| PFM Health Sciences, LP | 4,094,488 | $9,581,000 | 0.35% |
| RTW INVESTMENTS, LP | 5,106,341 | $11,949,000 | 0.28% |
| Omega Fund Management, LLC | 275,513 | $645,000 | 0.24% |
| Monarch Partners Asset Management LLC | 228,370 | $534,000 | 0.16% |
| Orbimed Advisors | 2,928,900 | $6,854,000 | 0.13% |